Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in Thalassemia Intermedia
NCT00661726Phase 2Completed
- Sponsor
- Elevance Health
- Start
- Jan 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of decitabine in thalassemia intermedia (TI), sponsored by Elevance Health. Primary endpoints: Number of Evaluable Patients With an Increase From Baseline in Hemoglobin (Hb) of ≥1.5 g/dL at 12 weeks and Change in Total Hemoglobin (Hb) From Baseline to Peak at 12 weeks. Started Jan 2008; status: completed.
02
Drugs
decitabine
03
Conditions
thalassemia intermedia (TI)
Beyond the preview
Go deeper on NCT00661726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661726.